CoChat
Sign Up
Cited by 224Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesRegulation of Appetite and Obesity

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

for the OBES-002 Study Group, Wilding, J, Gaal, L Van, Rissanen, A, Vercruysse, F, Fitchet, M·2004·International Journal of Obesity
DOI 10.1038/sj.ijo.0802783
Open this paper in CoChat — free account

Abstract

Background Treatment of obese subjects with topiramate has recently been associated with significant weight loss in a 6-month dose-ranging study.Objective To investigate the long-term efficacy and safety of topiramate in obese subjects.Design Randomised, double-blind, placebo-controlled study investigating three doses of topiramate: 96, 192, and 256 mg/day. All subjects also participated in a nonpharmacological weight-loss programme.Subjects The study included 1289 subjects 18-75 y with a body mass index >/=30 kg/m(2) and <50 kg/m(2) in the absence of comorbidities, or >/=27 kg/m(2) and <50 kg/m(2) in the presence of controlled hypertension and/or dyslipidaemia.Duration The original study design was for a 6-week, single-blind, placebo run-in phase followed by an 8-week titration phase and 2 y of maintenance at the assigned dose. Sponsor ended study early in order to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population. Therefore, none of the subjects completed the full 2 y of treatment. Efficacy results are based on subjects who were enrolled early enough to have had an opportunity to complete 1 y at their assigned dose (modified intent-to-treat population, MITT) before learning of the decision to terminate the study. Safety results are based on all subjects who took at least one dose of study medication.Results The safety population consisted of 1282 subjects, and the MITT efficacy population was 854 subjects. At 60 weeks, subjects in the placebo group lost 1.7% of their baseline body weight, while subjects in the topiramate 96, 192, and 256 mg/day treatment groups lost 7.0, 9.1, and 9.7%, respectively (P<0.001, MITT, last observation carried forward). Weight loss >/=5% of baseline weight was achieved by 18% of subjects in the placebo arm vs 54, 61, and 67% of subjects receiving topiramate 96, 192, and 256 mg/day, respectively; weight loss >/=10% was achieved by 6 vs 29, 40, and 44%, respectively (P<0.001). Weight loss was accompanied by significant improvements in blood pressure (systolic/diastolic changes of +0.4/+1.0, -3.1/-1.3, -5.7/-3.4, and -4.6/-2.4 mmHg were observed for placebo, topiramate 96 mg/day, 192 mg/day, and 256 mg/day, respectively, P<0.001) and glucose and insulin. The most common adverse events more frequently observed in topiramate-treated subjects occurred mostly during the titration phase and were related to the central or peripheral nervous system and included paresthesia, difficulty with concentration/attention, depression, difficulty with memory, language problems, nervousness, and psychomotor slowing.Conclusion Topiramate treatment of obese subjects over the course of 1 y resulted in clinically significant weight loss. Improvements were also observed in blood pressure and glucose tolerance.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.ijo.0802783

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 37 references

Cited by

Sorted by citations

Items 201–224 of 224

Related

See all

Metadata

Authors
for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M.
Affiliations
  • Aintree University Hospital (GB)
  • Helsinki University Hospital (FI)
  • Janssen Research & Development (United States) (US)
Corresponding author
Wilding, J
ORCID
Venue
International Journal of Obesity
Publisher
Springer Science and Business Media LLC
Published
2004-09-21
Volume
28
Issue
11
Pages
1399-1410
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
DOI
10.1038/sj.ijo.0802783
OpenAlex
W1980235427
Cited by
224
References
37
Citations by year
2026: 2 · 2025: 9 · 2024: 5 · 2023: 9 · 2022: 6 · 2021: 6 · 2020: 2 · 2019: 7 · 2018: 5 · 2017: 6 · 2016: 7 · 2015: 10 · 2014: 13 · 2013: 15 · 2012: 10
FWCI
12.77
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
topiramate, obesity, weight loss, anti-obesity drugs, long-term efficacy, drug safety, dose titration, controlled-release formulation, body mass index, hypertension, dyslipidemia, adverse events, tolerability, early trial termination, dose-ranging, antiepileptic drugs
MeSH terms
Topiramate, Adult, Blood Glucose, Blood Pressure, Depression, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Exercise Therapy, Female, Follow-Up Studies, Fructose, Glucose Tolerance Test, Humans, Male, Middle Aged, Obesity, Paresthesia, Suicide, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review